Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
SCHOLAR-2 trial: what clinicians have said so far
Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
- NCT04680442 ↗
- Recruiting
- Population Health Research Institute
- Standard size, estimated: 151–300 verified statements
We haven't built an HCP commentary report on SCHOLAR-2 (trastuzumab; pertuzumab; trastuzumab emtansine in breast cancer with overt left ventricular dysfunction) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SCHOLAR-2 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 15 posts on X | |
| 1 podcast episode |
The trial
ClinicalTrials.gov- Official title
- Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction: A Randomized, Controlled Trial
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Breast Cancer; Heart Failure
- Interventions
- Trastuzumab; Pertuzumab; Trastuzumab emtansine
- Arms
- Control Group · Active comparator
- Intervention Group · Experimental
- Enrollment
- 130 (estimated)
- Primary outcomes
- primary efficacy outcome
- co-primary safety outcomes
- Sponsor
- Population Health Research Institute
- Start
- Jul 1, 2021
- Primary completion
- Dec 31, 2025 (estimated)
- Results posted
- No
- Registry record
- NCT04680442 · updated Apr 6, 2025